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Abstract: Metabolomics techniques are now applied in numerous fields, with the ability to provide 
information concerning a large number of metabolites from a single sample in a short timeframe. 
Although high-frequency (HF) nuclear magnetic resonance (NMR) analysis represents a common 
method of choice to perform such studies, few investigations employing low-frequency (LF) NMR 
spectrometers have yet been published. Herein, we apply and contrast LF and HF 1H-NMR 
metabolomics approaches to the study of urine samples collected from type 2 diabetic patients 
(T2D), and apply a comparative investigation with healthy controls. Additionally, we explore the 
capabilities of LF 1H-1H 2D correlation spectroscopy (COSY) experiments regarding the 
determination of metabolites, their resolution and associated analyses in human urine samples. T2D 
samples were readily distinguishable from controls, with several metabolites, particularly glucose, 
being associated with this distinction. Comparable results were obtained with HF and LF 
spectrometers. Linear correlation analyses were performed to derive relationships between the 
intensities of 1D and 2D resonances of several metabolites, and R2 values obtained were able to 
confirm these, an observation attesting to the validity of employing 2D LF experiments for future 
applications in metabolomics studies. Our data suggest that LF spectrometers may prove to be easy-
to-use, compact and inexpensive tools to perform routine metabolomics analyses in laboratories and 
‘point-of-care’ sites. Furthermore, the quality of 2D spectra obtained from these instruments in half 
an hour would broaden the horizon of their potential applications. 
Keywords: low-frequency NMR; benchtop spectrometers; type 2 diabetes; metabolomics; 1H-1H 
COSY 
 
1. Introduction 
High-frequency (HF) 1H NMR analysis has been successfully developed to be applied in 
untargeted metabolomics investigations, through decades of successive optimisations with a wide 
range of biological media [1]. Metabolomics comprises both quantitative and qualitative analyses of 
whole metabolomes, which arise from a complex series of metabolic interactions and processes 
occurring within cells, tissues or organs. The overall purpose of metabolomics investigations is to 
detect, quantify and interpret variations in the concentrations of metabolites responsible for 
biological behaviour; the detection of perturbations or imbalances in metabolic pathways can reveal 
defects in the function or activities of selected enzymes therein, which may be characteristic of 
particular disease processes [2]. The detection of such defects may therefore lead to the identification 
of potential biomarkers, or the development of targeted diagnostic test systems for the diagnosis and 
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prognosis of diseases, processes which also give rise to improved understandings of their 
pathologies. This, in turn, may also lead to the identification of suitable drug targets [3]. 
Moreover, in addition to pathologies, such approaches may also provide a complete and 
systematic profiling of metabolites and their temporal changes caused by factors such as diet, 
lifestyle, environment and administered drugs. This is possible through the multicomponent analysis 
of body fluids and/or extracts of tissue biopsy samples, coupled with a statistical interpretational 
strategy known as multivariate analysis [4]. In view of its multicomponent analytical advantages, HF 
NMR analysis serves as a powerful tool for the simultaneous and rapid identification and 
quantification of large numbers of biomolecules present in biofluids or tissue sample extracts. Hence, 
it is ideal for probing the metabolic profiles of complex samples collected from living systems, for 
diagnostic or prognostic purposes [5,6]. 
HF NMR spectroscopy has long been employed to conduct metabolomics studies, and offers 
many further significant bioanalytical advantages for such applications. Indeed, the technique is 
virtually non-destructive, and requires a short analysis time, and for biofluids, usually requires very 
little sample preparation [7]. However, HF NMR analysis also presents a number of disadvantages, 
such as cost, size, and transportation limitations, and often the requirement for specialist technical 
staff for instrumental operation. Moreover, the size of such high-resolution NMR facilities limits their 
accessibility to many researchers, and therefore precludes regular use outside of university-based 
NMR-dedicated laboratories, along with those in large industrial centres. 
Low-frequency (LF) applications of NMR have previously been explored in some detail [8–10], 
and the future of NMR-based metabolomics has also been recently discussed, with an emphasis on 
this approach providing a convincing solution for metabolic fingerprinting at ‘point-of-care’ sites or 
prospectively, even for personal use [11–13]. Moreover, LF 1H NMR applications have recently been 
shown to distinguish between control and type 2 diabetic (T2D) participants, with potential use for 
point-of-care applications in a metabolomics study using a near-portable benchtop NMR 
spectrometer as a novel bioanalytical tool [11]. The advantages of this technique included fast 
acquisition time, ease-of-use and low limits of detection [11]. Moreover, LF benchtop NMR facilities 
do not require expensive cryogens, nor a Gauss safety line for the magnetic field, and much less 
power is required for operation, achieving desirable low running costs for potential applications in 
clinical chemistry. However, although acceptable correlations between urinary metabolite calibration 
standard concentrations, and selected prominent metabolites detectable in urine itself, particularly 
those of glucose, were found between the LF and HF analyses conducted, the overall metabolomics 
results obtained in this study at an operating frequency of 60 MHz were not directly validated by 
comparisons with those arising from the application of a corresponding HF NMR facility. f especial 
interest is an evaluation of whether the nature of detectable metabolites, and the number of these 
found as discriminant markers in the 60 MHz study, were comparable to those found using HF NMR 
analysis. Furthermore, disadvantages of the one-dimensional (1D) approach included a lack of 
resolution, or more specifically a range of resonance overlap and crowding problems encountered in 
LF analysis. Indeed, it was not possible to resolve the β-glucose anomeric proton signal from the 
residual water resonance. However, the use of such 1D LF techniques for many qualitative analyses, 
as well as the development of appropriate and robust automated computational tools for real-time 
analysis, have the potential to impact on a myriad of additional applications. 
In this pilot study, we first investigate LF and HF datasets robustly, in order to compare the 
accuracies and precision of statistical tools via the acquisition of urinary spectra at both operating 
frequencies. We also present results regarding improvements in spectral resolution, which are 
achievable via the acquisition of 2D NMR urinary profiles through LF 1H-1H correlation (COSY) 
spectra. This paper complements the preliminary metabolomics results reported by Percival et al. 
[11], and describes for the first time the fully assigned 2D spectra acquired at LF, in addition to a 
robust comparison between metabolomics studies performed at both operating frequencies. Results 
presented in this manuscript are therefore sub-divided into three sections. The first phase of the study 
investigates the capabilities and analytical advantages of 2D NMR spectra acquired at low-field, 
whilst the second phase compares the results of metabolomics analyses performed at both LF and HF 
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NMR operating frequencies. The final phase is based on the results obtained from Phase 2, and, 
partial least square (PLS)-regression analysis, is conducted in order to determine the relationship 
between glucose concentrations detectable in the urinary 1H NMR profiles of T2D patients, and also 
modifications in the urinary excretion of other metabolites. 
2. Results 
2.1. Analysis of 2D “POWER COSY” 60 MHz LF Spectra 
2D NMR measurements were acquired on 10 T2D patient urine samples, using gradient- 
enhanced magnitude for 1H-1H COSY experiments. As shown in Figure 1, at least several metabolites 
can be identified via their corresponding diagonalized resonances, and correlation signals are 
observed for those present at high urinary concentrations, such as glucose, as well as a four-bond 
connectivity (long-range connectivity cross-peak) for creatinine at [3.06,4.06] ppm. Interestingly, 
apparent doublet resonances were observable in the LF one- and two-dimensional NMR spectra, but 
not in the corresponding HF equivalents. Indeed, two regions of the spectrum, at δ = 5.55–5.72 and 
4.24–4.40 ppm, appeared to be “mirrored” by a specific region of the spectrum within the 5.13–5.29 
ppm range. In T2D patients, with the doublet at 5.25 ppm assigned to the α-glucose anomeric C1-H 
proton, these signals appear in 1D spectra as a “mirroring” doublet of the α-glucose anomer’s signals 
located at δ = 4.3 and 5.7 ppm, and a corresponding cross-peak signal was observed in the 2D COSY 
spectrum (Figure 1A,B, respectively). Moreover, it should be noted that the urea resonance located at 
δ = 5.7 ppm, which is readily detectable in the HF spectra, is much less visible in the 60 MHz profiles 
in view of this interfering signal, which as expected, is certainly not observed when glucose is not 1H 
NMR-detectable in urine samples (Figure 1B). 
Integration of the glucose (α-glucose [5.25,3.58]; bulk glucose ring protons [3.20,3.98] ppm) and 
creatinine ([3.06,4.06] ppm) 2D cross-peaks signals, and those of corresponding 1D proton intensities, 
was followed by their normalization to the internal TSP reference signal. Notably, β-glucose proton 
integration values could not be used for quantification purposes, in view of a significant overlap with 
the residual water signal at 60 MHz operating frequency. Furthermore, a 1D integration of the 
creatinine signals was performed on the 3.06 ppm >N-CH3 resonance only, since that of the -CH2 
function at 4.06 ppm was subject to overlap from those arising from glucose bulk-chain protons. 
Relationships between these 2D cross-peak intensities and those of matched 1D proton signals were 
investigated by linear correlation analysis. As shown in Figure 1, regression lines show strong 
correlations between the TSP-normalised 1D and corresponding 2D integrals, with R² values of 0.96, 
0.95 and 0.81 for α-glucose, the bulk glucose ring protons, and creatinine (Figure 1C, E and D 
respectively). 
As noted above, the 4.60 ppm β-glucose signal cannot be integrated in 1D spectra, in view of a 
very high level of overlap with the residual water resonance in this region. However, the 2D cross-
peak resonance is clearly observable in 2D COSY spectra acquired, as shown in Figure 1. To assess 
whether the proximity of the water signal also interferes with the β-glucose intensity in 2D spectra, 
linear correlation analyses of the intensity of the 2D cross-peak of β-glucose versus those of α-glucose 
or the bulk glucose ring were performed. Excellent correlations were found, with R2 values for the 
relationships of β-glucose with α-glucose and bulk glucose ring protons being 0.92 and 0.96 
respectively (Figure 1E,F respectively). The unusual δ = 4.3 and 5.70 ppm resonances were also 
strongly correlated with the δ = 5.13–5.29 ppm spectral region (R2 = 0.96 and 0.97 respectively), and 
these data provide evidence for its glucose source. Association between these spectral zones was 
evaluated by computing the 1D integral ratio of α-glucose with these signals’ integral intensity ratios, 
i.e., 5.25/5.70 or 5.25/4.38 ppm. Based on this, spectral intensities at the 5.70 ppm integral revealed a 
mean intensity of 22.4 ± 3.6% (mean ± SEM values) of that at 5.25 ppm, whereas the integral value for 
the δ = 4.38 ppm resonance was 11.6 ± 1.7% of that at 5.25 ppm. Overall, this analysis confirmed that 
these three separate spectral zones are strongly correlated. However, although correlated with 
glucose’s α-anomer C1-H resonance, these two unusual coupled doublet signals (J = 4.23 Hz) are not 
simply explicable, and therefore further experiments are required to establish their precise identity. 
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In principle, the gradient (regression coefficient) of the plot of the intensity of the β-glucose C1-
H anomeric proton 2D cross-peak (δ = 4.66 ppm), versus that of the corresponding 5.25 ppm α-glucose 
one, should reflect their natural abundancies, i.e., 64%:36% = 1.64. However, this gradient was only 
0.60, and this much lower value arises from the β-anomer 1D resonance being much closer to the 
water presaturation frequency (δ = 4.74 ppm) than that of the α-anomer. The marked influence of the 
presaturation process on the intensity of the 1D α-glucose resonance has already been explored in 
detail in Ref. [11], at both 60 and 400 MHz operating frequencies. 
 
Figure 1. Investigation of 2D 1H-1H COSY low-frequency NMR spectra. (A): 2D 1H-1H COSY NMR 
T2D urinary profile acquired at 60 MHz using a benchtop NMR facility. Creatinine blue squares 
represent the long-range connectivity cross-peak for this metabolite. Blue squares labelled A represent 
unassigned, unusual doublet resonances arising from ‘mirroring’ spectral signal located at δ = 5.13–
5.29 ppm (in this case, reflecting the α-glucose cross-peak). (B): Unassigned 4.38 and 5.70 ppm doublet 
resonances, detectable in the 1D 60 MHz NMR profile of a urine sample collected from a 
hyperglycaemic T2D patient, but completely absent from that of a healthy control participant. Urea, 
which is observable in HF 400 MHz spectra and resonates at ~5.80 ppm, was not readily observable 
in our LF spectra in view of its broadness and overlap with the unassigned δ = 5.70 ppm signal. Typical 
spectra are shown. (C) and (D): Linear correlations between 1D and 2D integrals of α-glucose’s C1-H 
5.25 ppm resonance (C), and that of creatinine’s N-CH3 function at δ = 3.06 ppm (D). (E) and (F): Linear 
Metabolites 2020, 10, 155 5 of 13 
 
correlations between 2D cross-peaks signal integrals of β-glucose’s C1-H signal versus those of 
glucose bulk ring (E), and α-glucose’s C1-H function (F). 
2.2. Metabolomics Investigation of T2D versus Healthy Urine Samples: Low- and High-Frequency 1H NMR 
Comparisons 
Urinary 1H NMR spectra of 10 non-rigorously controlled T2D patients and 15 self-reported 
healthy control participants were acquired using both 60 and 400 MHz spectrometers. Spectral 
comparisons between both frequencies, along with a table of identified metabolites, is shown in the 
Supplementary Material (Figure S1). In order to determine whether the metabolomics analysis 
performed effectively on spectra acquired on a LF benchtop NMR facility, and provides results 
comparable to those of a HF instrument, a comparative multivariate statistical analysis of datasets 
was performed, and the results acquired compared. An orthogonal partial-least squares discriminant 
analysis (OPLS-DA) scores plot (component 2 versus component 1) featuring both T2D and control 
participants revealed identical spatial localizations of the patients, under both HF and LF conditions 
(Figure 2). Samples could be separated into two clear clusters according to their health status along 
the first PC, and these acquired results appeared to be similar for experiments conducted at both 
spectrometer operating frequencies (Figure 2A,B). Moreover, analysis of the second component 
showed a wide intra-group variation within diabetic samples, with the appearance of two sub-
clusters within this classification. A further analysis revealed that these two sub-clusters arose from 
diabetic patients presenting with high urinary glucose concentrations, and those with only little or 
none of this metabolite detectable. The cluster separation of T2D and control samples is clearly 
observable under both LF and HF conditions, with LF model R² and Q2 values of 0.924 and 0.611, 
respectively, and similar HF model values of 0.943 and 0.706, respectively (for models with a total of 
three components). 
Most relevant variables linked to this separation were extracted from an S-line correlation and 
VIP plots. In the S-curve, the main metabolites contributing to the separation were identified with 
higher values of correlation coefficients (denoted by a red colouration in (Figure 2C,D). Moreover, 17 
and 16 variables of interest with VIP values > 1 were identified for high- and low-frequency 
conditions, respectively. Of note, only one variable of interest differs between the HF and LF 
condition: the 5.86 ppm urea bucket stands out as a discriminator only in the HF NMR dataset 
acquired, and this is not unexpected in view of its detectability only at the latter operating frequency. 
From these variables, 5 (LF) and 6 (HF) potentially discriminant metabolites were identified. 
Indeed, glucose is increased in T2D patients, whilst levels of citrate, creatinine, indoxyl sulfate, urea 
(only observed in HF analysis) and hippurate are significantly reduced (Figure 2C,D). With the 
exception of urea, the metabolites responsible for the separation observed between these clusters 
were similar in both datasets acquired. Model validity was assessed via permutation testing (1000 
permutations, HF Q2 value p < 0.001; LF Q2 value p < 0.001) and ROC analysis (Figure 2E,F). ROC 
curves generated via Monte Carlo cross-validation (MCCV) and based on the PLS-DA strategy (using 
2 latent variables) demonstrated that the overall mean classification success rate was 92% and 90% 
for the HF and LF 1H NMR models, respectively. 
The most effective PLS models were those incorporating 25 bucket regions, the AUROC value 
obtained being 0.96 for spectra acquired by HF, and 0.94 when using LF NMR analysis (95% 
confidence intervals 0.81–1.00). Therefore, based on the AUROC values and the overall Q2 and R2 
scores obtained above, both models revealed a highly effective discriminatory ability. In view of 
complications arising from the very prominent glucose resonances present in approximately one-half 
of the T2D urinary 1H NMR profiles, and the application of the CSN (constant sum normalisation) 
approach, we elected to perform a corresponding statistical analysis on the full dataset after removal 
of all glucose resonance bucket regions. Indeed, following the removal of these resonance regions, 
the dataset was again constant sum-normalized and Pareto-scaled. Briefly, the results acquired 
confirmed significantly diminished urinary concentrations of hippurate (p < 0.005 to < 0.05 for three 
bucket regions) and indoxyl sulfate (p < 0.007 to < 0.05, again for three bucket regions). This univariate 
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analysis was performed on all remaining (non-glucose) resonances using false discovery rate (FDR)-
corrected two-samples t-tests. 
We also directly compared the mean TSP-normalised intensities of ‘bulk resonance bucketed’ 1H 
NMR signals between the HF 400 and LF benchtop 60 MHz spectrometers employed for this study 
in a univariate manner via a paired sample t-test, and found that the only significant ‘between-
spectrometer’ difference observed was that between the δ = 2.89 ppm trimethylamine N(CH3)3 singlet 
resonance, this value being greater for the 60 MHz spectrometer (FDR-corrected p value 0.002). 
However, this difference can be rationalized by its close location to the relatively intense joint 
creatinine/creatine >N-CH3 signal (δ = 3.03 ppm), which at an operating frequency of only 60 MHz, 
will be expected to provide a significant contribution towards the intensity of that of TMA. For this 
analysis, a series of 12 pre-selected resonances (of signal-to-noise (STN) values ≥ 10) were compared, 
and the dataset was also generalized logarithmically (glog)-transformed and Pareto-scaled prior to 
analysis. 
 
Figure 2. Metabolomics analysis of T2D 1H NMR urinary profiles (n = 10), versus those of healthy 
controls (n = 15), acquired using HF and LF NMR spectrometers. Scores plots (A and B), and 
corresponding loading-plots (C and D) from orthogonal partial-least squares discriminant analysis 
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(OPLS-DA) applied to 1H-NMR spectra of control versus T2D samples, acquired using HF (A and C) 
or LF (B and D) 1H NMR analysis. The colour of the signals in the loading plots correspond to the 
metabolites contributing most greatly towards the separation between T2D and healthy control group 
samples. The colour bar next to the right-hand side of these plots indicates the level of importance of 
the metabolites discriminating between classes (either positively or negatively so), the least significant 
represented by a blue colouration, and the most highly significant metabolites, red. (E) and (F):: 
Receiver operating characteristic (ROC) curve (with an area under ROC curve (AUROC) value of 0.96 
(E, HF NMR acquisition) and 0.94 (F, LF NMR acquisition) obtained from the PLS model building 
system, explored with 25 discriminant variables. 
2.3. Linear Correlations of Glucose Levels with the Urinary Metabolome of Diabetic Patients 
Potential relationships between the urinary levels of glucose, measured independently with a 
spectrophotometric GOD-PAP method as a clinical chemistry standard, and the urinary metabolomic 
profiles acquired were evaluated by conducting transversal correlation studies. These correlations 
were obtained by performing PLS regression (PLS-R) using only the non-glucose resonance NMR 
spectral regions of diabetic urinary samples included as the X-matrix, and the non-NMR-determined 
glucose levels as the Y-matrix; spectral regions of the glucose resonances (3.12–4.00, 4.15–4.35 and 
5.10–5.40 ppm) were removed from the X-matrix prior to analysis, and the complete remaining 
dataset was then again constant sum-normalised and Pareto-scaled. It should also be noted that the 
glucose values vary greatly (spanning from 0.15 to 251 mmol/L), and hence were logarithmically-
transformed to facilitate linear regression analysis. Two T2D samples with a glucose concentration 
value of 0 were excluded from the study. As shown in Figure 3, PLS regression lines for glucose levels 
correlate strongly with the urinary metabolome of all n = 8 T2D patients, with R² coefficients of 0.99 
and 0.89 when using HF or LF spectra, respectively (Figure 3A and B respectively). On the basis of 
the VIP plots, variables with values ≥ 1 were selected as key ones related to urinary glucose variation. 
A total of 18 variables were determined as significant, and from these, 5 metabolites identified were 
found to be correlated with urinary glucose levels. Indeed, creatinine, alanine, citrate, lactate and N-
acetylsugar/N-acetylamino acid resonances all appeared to be negatively correlated with urinary 
glucose levels. Hence, diabetic patients presenting with lower levels of urinary glucose display 
increased levels of hippurate, indoxyl sulfate, citrate and lactate levels, when compared to patients 
with high glucose values. 
 
Figure 3. Transversal correlation studies between the T2D urinary metabolome and urinary glucose 
levels. PLS regressions were used to determine correlations between the glucose levels (Y actual 
values, on the y-axis) and the urinary metabolome of diabetic patients (depicted as Y predicted, on 
the x-axis) from spectra acquired by HF (left panel) or LF NMR analyses (right panel).  
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3. Discussion 
Metabolomics is a powerful approach which, in the space of a few decades, has developed 
considerably, and HF NMR analysis is one of the most commonly applied techniques to perform 
metabolomics studies. However, despite adoption in several domains, the application of LF 
spectrometers for this purpose remains limited [8,11,13]. Here, we have reported metabolomics 
analysis comparisons between the 1H NMR profiles of T2D and control participant urine samples 
acquired by both high- and low-frequency NMR techniques. In our chemometrics analysis, T2D urine 
samples are readily distinguishable from those of healthy controls, and several metabolites are linked 
to this separation. Indeed, while glucose levels are higher in T2D patients, those of hippurate and 
indoxyl sulfate are lower in these participants. These results are observable in both HF and LF spectra, 
with OPLS-DA scores plots presenting highly similar spatial localizations of each sample at both 
operating frequencies, as well as corresponding discriminatory metabolites, with the exception of 
urea. Hence, under the same bucketing and normalisation conditions, it is possible to attain 
comparable results at both high and low operating frequencies. However, several limitations of this 
study should be considered, primarily, a probable insufficient sample size was involved, and the high 
levels of glucose present in some of the T2D urine specimens renders a facile multivariate 
metabolomics separation between the two conditions. The robustness of this approach still requires 
further testing on a large number of samples, and in a study investigating more non-glucose-based 
metabolic changes. Nevertheless, this challenges the paradigm of HF NMR applied in metabolomics, 
and also provides potential scope and insight for the development of new metabolomics strategies 
employing faster, cheaper and easier to use NMR techniques. 
Poorly controlled diabetic patients regularly suffer from nocturia and polyuria, the former a 
condition in which patients awaken at least once during the night to void urine [14]. These lead to 
decreases in the concentrations of many urinary metabolites, together with wide ’between-
participant’ variations in urinary excretion volumes. This may explain why T2D group 
downregulations in hippurate and indoxyl sulfate are also responsible for the ‘between-disease class’ 
distinction observed here, with significantly higher concentrations observed in the healthy control 
group. One approach to adjust for this would be to normalize the dataset using creatinine levels, 
which are usually excreted steadily in the urine. However, this was not possible in our study for the 
spectra acquired by LF NMR analysis, since the two buckets corresponding to this biomolecule’s 
resonances at δ = 3.06 and 4.06 ppm were subject to several overlap instances with other metabolites, 
i.e., those with resonance frequencies close to those of these signals. This is highlighted by the linear 
correlation observed between the integrals of the 1D versus 2D cross-peaks for creatinine, since the 
resulting correlation coefficient value is lower when compared to other corresponding plots obtained. 
This can be rationalised by considering several closely located metabolites signals, such as creatine 
and glucose, that are also likely integrated within the creatinine signal chemical shift region in 1D 
analysis, whilst integration of the 2D cross-peak signal serves to limit the superposition of resonances 
related to other metabolites. Furthermore, approximately 25% of diabetic patients suffer from kidney 
dysfunction [15], which is known to affect creatinine clearance [16], a phenomenon further hindering 
any creatinine normalisation strategies in metabolomics studies involving diabetic patients. 
In the present study, urinary glucose levels were positively correlated with the non-glucose 
urinary metabolome of T2D samples. In particular, the abundance of several metabolites was 
downregulated based on glucose levels excreted in patient urine samples. High levels of glucose in 
the urine serve as commonly employed markers of poorly-controlled diabetes. These metabolites 
could correspond to the excretion of biomarkers of cellular or tissular dysfunctions, or defects linked 
to diabetes management. Further studies with larger sample sizes are therefore required to confirm 
the significant discriminatory metabolites identified in this case, since they may constitute valuable 
biomarkers for mechanistic studies, and the clinical monitoring of patients with type 2 diabetes. 
Furthermore, as noted above, multivariate correlation studies reveal that T2D patients presenting 
with lower levels of glucose display increased levels of hippurate, indoxyl sulfate, citrate and lactate, 
when compared to those with high glucose values. In our metabolomics analysis, OPLS loadings 
revealed that these urinary metabolites are at higher levels in the healthy control group, when 
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compared with T2D participants. Therefore, this observation may suggest that glycaemically-
controlled T2D patients with higher levels of these metabolites (and correspondingly lower urinary 
glucose levels) display a metabolomics profile more closely related to that of healthy control patients, 
and hence potentially reveals a better managed or controlled disease status. 
The linear correlation analysis performed between the 1D and 2D intensities of glucose, bulk 
ring glucose and creatinine resonances showed strong correlations, except for that observed with 
creatinine, as noted above, which attests to the validity of 2D spectra acquired with the sequence 
“POWER COSY”. In addition, the acquisition of 2D 1H-1H NMR profiles clearly gives rise to an 
improvement in the resolution of the signals observed, and in particular allowed for the integration 
of the cross-peak signal of β-glucose, which was not possible in 1D spectra in view of overlap of its δ 
= 4.63 ppm anomeric proton signal with that of the residual water resonance in this spectral region. 
It should also be noted that apart from creatinine and glucose, the cross-peaks of other metabolites 
present at lower concentrations are not observable in the 2D spectra acquired. The sensitivity of the 
2D spectra is lower than that of the 1D approach [17], and this is presumably why only the cross-
peaks of the metabolites present in large quantities are observable. However, these spectra were 
acquired with only eight scans in only 30 min., and therefore increasing the number of scans may 
permit the observation of cross-peaks of several other metabolites. In addition, a metabolomics 
analysis of 2D COSY spectra acquired by HF has previously been developed [18,19], and these 
strategies could, in principle, also be applied to LF spectra, which could conceivably assist researchers 
in the context of overcoming the overlapping resonance issue encountered in 1D LF spectra, and also 
possibly increase the number of discriminatory metabolites discovered in such LF metabolomics 
investigations. 
Problems encountered with the 1H NMR detection of urea at LF are explicable by the presence 
of unassigned doublet resonances detectable at this operating frequency. Hence, the removal of this 
signal may render urea analysis in such T2D urine samples possible. Since these signals are located 
close to the residual water signal, they may also be related to the solvent suppression sequence 
employed, and therefore further investigations are required to evaluate these effects. Unfortunately, 
such errors constitute a bias that must be considered when confirming the identities of 1H NMR 
signals and/or metabolomics investigations. 
Finally, our results suggest that LF spectrometers could provide excellent, easy-to-use, compact 
and inexpensive tools to perform preliminary diagnostic analyses, either in laboratories or at external 
locations. Moreover, the quality of 2D spectra obtained within only a few minutes would broaden 
the horizon of its potential applications, such as drug analysis [20], or applications in the 
environmental [21] or nutrition fields [13]. As demonstrated here, 2D NMR spectral analysis could 
also contribute to personalised medicine and translational metabolomics in the areas of healthcare or 
dentistry. However, there remain a number of major drawbacks that limit their application in routine 
metabolomics analysis, such as low biomarker sensitivities and J-couplings which are spread over a 
much wider range of the total spectral width (for example, as much as 0.20 ppm for a triplet resonance 
with a J value of 6 Hz), phenomena which limit the number of detectable metabolites in a single 
sample. Therefore, these major issues must be addressed in the near future, in order to allow LF NMR 
diagnostic technologies to gain momentum in clinical applications. 
4. Materials and Methods 
4.1. Study Design 
All samples in this study were collected with informed consent and approved by the appropriate 
Research Ethics Committee, specifically the Faculty of Health and Life Sciences Research Ethics 
Committee, De Montfort University, Leicester, UK (reference no. 1936). All participants were 
primarily provided with participant information sheets (PISs), and were then required to sign a 
project consent form in the presence of a researcher witness. The PIS clearly informed those recruited 
that since their participation was voluntary, they had the freedom to withdraw from the investigation 
at any stage of the process. All participants were also requested not to consume any alcoholic 
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beverages, nor any dietary sources known to affect the human metabolome, for 24 hr. prior to urine 
sample collection. Essentially, all ethics considerations were in accordance with those of the 
Declaration of Helsinki of 1975 (revised in 1983). 
4.2. Urine Collection 
Participants fasted for a minimum period of 12 hr. prior to sample collection. Urine samples 
were collected from healthy control (n = 15) and T2D patients (n = 10), in sterile, plastic universal 
containers (King Scientific, Huddersfield, UK). These specimens were then transported to the 
laboratory on ice, and centrifuged immediately (3500 rpm at 4 °C for 15 min.). The supernatants were 
finally stored at −80 °C prior to 1H NMR analysis. 
4.3. Spectrophotometric Determination of Glucose 
Glucose was quantified using the well-established glucose oxidase-peroxide/4-
aminophenazone/phenol (GOD-PAP) spectrophotometric methodology, which is outlined in 
Percival et al. [11] A glucose calibration curve, of concentrations ranging from 0.50 to 2.5 mg/mL, 
were prepared in 0.90% (w/v) NaCl (glucose was purchased from Sigma-Aldrich Chemical Co., 
Gillingham, UK). A 0.50 mL volume of the GOD-PAP reagent was incubated at 37 °C (Stuart Scientific 
Incubator SI 19, Stone, UK) for 10 min. in a polystyrene cuvette (1.0 mL path length, Fisher Scientific, 
Loughborough, UK). Then, 5 µL of each calibration standard was added to the cuvettes and incubated 
for a further 10 min. at 37 °C. Cuvette solutions were homogenized and equilibrated for a further 10 
min. at 37 °C. Subsequently, these solutions were analysed using a spectrophotometer (Evolution 60S, 
Thermo Fisher Scientific, Leicester, UK), at a wavelength of 510 nm. The same procedure described 
here was followed for urine samples, using 5 µL of urine in place of glucose calibration standard 
solutions. The calibration curve had an R2 value of 0.990. 
4.4. Low-frequency (60 MHz) 1H-NMR Analysis 
Optimised sample preparation techniques for urine samples have been previously described 
elsewhere [11]. Briefly, 1H NMR spectra were acquired using a 60 MHz Magritek benchtop facility 
(Spinsolve Ultra Proton), operating at a frequency of 61.67 MHz. For the urine samples, a 90:10% (v/v) 
ratio of H2O:D2O was used, the latter also containing 0.05% (w/v) sodium 3-trimethylsilyl-(2,2,3,3-
2H4)-1-propionate (TSP). Samples were prepared at an ambient temperature in 5-mm diameter NMR 
tubes. Sample parameters for the 1D 1H NMR analysis were as follows: 64 scans, acquisition time of 
6.4 s, repetition time 10 s, and a pulse angle of 90°, as previously described [11] pectra were acquired 
using a one-dimensional presaturation (1D PRESAT) sequence, to allow for efficient saturation of the 
water signal, and the water-suppression pulse was placed during the relaxation delay (1 s). 
A gradient-enhanced magnitude COSY experiment (pulse sequence cosy 1H-1H Power Cosy, 
supplied by Magritek GmbH) was employed for the acquisition of 2D 1H-1H spectra. Spectra were 
collected with 8192 datapoints in F2, and 256 points in F1, over a sweep width of 14 and 46 ppm 
respectively; 8 scans were performed per F2 value, along with 4 dummy scans and a receiver gain of 
101. The acquisition time was 0.16 and 1.63 s for F1 and F2, and the free induction decay (FID) 
resolution was 0.61 and 7.81, respectively. Resulting 1H-1H COSY spectra were processed in Topspin 
4.0.6 and ACD labs 12.0 software modules using standard approaches, with sine-squared apodization 
in both dimensions, and zero filling in F1 to yield a transformed 2D dataset of 8192 by 256 datapoints. 
4.5. High-frequency (400 MHz) 1H-NMR Analysis 
Identical preparation techniques were used for the HF 1H NMR analysis. Sample parameters for 
the 1D noesygppr1d HF 400 MHz analysis are detailed elsewhere [11]. Briefly, samples were acquired 
using 128 scans, with a size of 32,768 over a spectral width of 12.11 ppm, using an acquisition time of 
3.38 s. and a receiver gain of 128 on a 400 MHz NMR facility (Bruker Avance I, Coventry, UK), 
operating at 399.93 MHz. Solvent suppression was employed in order to diminish the signal arising 
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from water at δ = 4.80 ppm. Samples were placed in 5 mm NMR tubes and were analysed at random 
using an autosampler. 
4.6. Multivariate Metabolomics Analysis 
The same preprocessing and multivariate analysis strategies were applied to both LF- and HF-
acquired FIDs. For statistical analysis, FIDs were converted and imported into Bruker using the 
“JCONV” command. They were processed with the Bruker Topspin 4.0.6 software with a standard 
parameter set. Phase and baseline corrections were performed manually over the entire range of the 
spectra, and the δ scale was calibrated to 0 ppm, using the internal standard TSP. Optimized 1H-NMR 
spectra were imported into ACD Labs 12.0 (Toronto, ON, Canada). Fixed bucket spectral intensities 
were then normalized to total intensities (also known as constant sum normalisation), and reduced 
to integrated regions of equivalent spectral width (0.04 ppm), corresponding to the 0.50–10.00 ppm 
range. The reduced and normalized NMR spectral data were imported into SIMCA (version 13.0.3, 
Umetrics AB, Umea, Sweden). Pareto-scaling was applied to bucketed data, and a multivariate 
metabolomics analysis, including principal component analysis (PCA) and an orthogonal partial-
least squares discriminant analysis (OPLS-DA) were performed. SIMCA was used to generate all 
PCA, OPLS-DA and partial least-squares regression (PLS-R) model analyses, and corresponding 
plots. PCA was used to detect possible outliers and visualise intrinsic clusterings within the dataset, 
whilst OPLS-DA maximized the separation and facilitated the graphic visualization of differences 
and similarities between groups. The quality of OPLS-DA models was determined by goodness of fit 
(R2) values; the predictability of these were calculated on the basis of the fraction correctly predicted 
in a one-seventh cross-validation process (involving Q2 determinations). Ordinary linear regression 
approaches were performed using Excel 2016 (Microsoft Corporation, Redmond, WA, USA). All 
univariate statistical analyses were conducted using the freely available web-tool Metaboanalyst 
(metaboanalyst.ca) 
By using the web-based analysis tool, Metaboanalyst (www.metaboanalyst.ca), receiver 
operating characteristic (ROC) curves were generated to assess the robustness of the models. ROC 
analyses were based on PLS-DA models, as classification methods with 2 latent variables (i.e., major 
orthogonal components). Model sensitivity and specificity were calculated from the ROC confusion 
matrix (generated on the basis of the average of predicted class probabilities of each sample across 
100 cross-validations). ROC curves were generated by Monte Carlo cross validation (MCCV), using 
balanced sub-sampling. In each MCCV, two thirds (2/3) of the samples were used to evaluate feature 
importance. The top 2, 3, 5, 10 ...100 (max) important features were then used to build appropriate 
classification models, which were then validated on the one-third of the samples that were left out. 
This procedure was repeated multiple times to calculate performance and associated 95% confidence 
intervals (CIs) for each model system. 
4.7. Metabolite and Discriminatory Biomarker Identification 
From PLS-DA and OPLS-DA loading plots, metabolites with higher loadings values were 
identified. Signals with variable importance in projection (VIP) values ≥ 1 were considered as 
significant, and further validated using two-sample t-tests within Metaboanalyst. Metabolite 
identification was then performed using the open-access database NMRsuite 8.1 (Chenomx inc., 
Edmonton, AB, Canada), the free web-based tool Human Metabolome DataBase (HMDB) 
(http://www.hmdb.ca), and a full consideration of substantial chemical shift and coupling constant 
values available throughout the literature. 
5. Conclusions 
NMR spectroscopy is a powerful and reliable tool to assess the molecular compositions of 
biosamples using multivariate metabolomics strategies. In this study, we assessed the capabilities of 
a metabolomics analysis of data acquired on a LF benchtop NMR spectrometer using both 1D and 
2D strategies, and compared results from these investigations to those obtained on a much higher 
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frequency spectrometer. We also evaluated the strengths and limitations of LF 2D COSY spectra 
acquired for this purpose. Overall, our findings highlight the ability of a LF NMR approach to 
successfully reproduce metabolomics results achieved using a HF option. Moreover, the 2D COSY 
spectra of urinary diabetic samples gave rise to an improved level of identification and sensitivity, in 
relation to the resonances affected or partially overlapped by the more prominent glucose ones 
observed in 1D spectra. Further improvements in the numbers of metabolites detectable, and also the 
sensitivity of such LF NMR techniques, will, however, be achievable with greater numbers of 
acquisitional 1H-1H 2D COSY scans. Finally, development and applications of LF spectrometers are 
rapidly gaining momentum, and other metabolomics studies are very likely to be performed on this 
technique in the near future. 
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